Synthesis of 2-aminopropyl benzopyran derivatives as potential agents against triple-negative breast cancer

被引:1
|
作者
Garcia, Ainhoa [1 ,2 ]
Torres-Ruiz, Sandra [2 ]
Vila, Laura [2 ]
Villarroel-Vicente, Carlos [1 ,2 ]
Bernabeu, Alvaro [1 ]
Eroles, Pilar [2 ,3 ,4 ]
Cabedo, Nuria [1 ,2 ]
Cortes, Diego [1 ]
机构
[1] Univ Valencia, Dept Pharmacol, Valencia 46100, Spain
[2] Univ Clin Hosp Valencia, Inst Hlth Res INCLIVA, Valencia 46010, Spain
[3] Univ Valencia, Dept Physiol, Valencia 46010, Spain
[4] Ctr Biomed Network Res Canc CIBERONC, Madrid 28019, Spain
来源
RSC MEDICINAL CHEMISTRY | 2023年 / 14卷 / 11期
关键词
DRUG DISCOVERY; APOPTOSIS; GENISTEIN; FAMILY; INHIBITORS; ESTROGEN; PATHWAY;
D O I
10.1039/d3md00385j
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Synthesis of three series of 2-aminopropyl derivatives containing a benzopyran nucleus was performed to evaluate their performance against triple-negative breast cancer cell lines (MDA-MB-231 and MDA-MB-436) and normal breast epithelial cells (MCF10A). For the three series, the cytotoxic activity was as follows: N-methylated derivatives (tertiary amines) 5b, 6b, and 7b > secondary amine benzopyrans 5, 6, and 7 > quaternary amine salts 5c, 6c, and 7c > free phenolic derivatives 5a, 6a, and 7a. The structure-activity relationship showed the importance of the presence of an amine group and a p-fluorobenzyloxy substituent in the chromanol ring (IC50 values from 1.5 mu M to 58.4 mu M). In addition, 5a, 5b, 6a, and 7b displayed slight selectivity towards tumor cells. Compounds 5, 5a, 5b, 6, 6a, 6c, 7, and 7b showed apoptotic/necrotic effects due to, at least in part, an increase in reactive oxygen species generation, whereas 5b, 5c, 6b, 7a, and 7c caused cell cycle arrest in the G1 phase. Further cell-based mechanistic studies revealed that 5a, 6a, and 7b, which were the most promising compounds, downregulated the expression of Bcl-2, while 5b downregulated the expression of cyclins CCND1 and CCND2. Therefore, 2-aminopropyl benzopyran derivatives emerge as new hits and potential leads for developing useful agents against breast cancer.
引用
收藏
页码:2327 / 2341
页数:15
相关论文
共 50 条
  • [41] Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
    Li, Chia-Jung
    Tzeng, Yen-Dun Tony
    Chiu, Yi-Han
    Lin, Hung-Yu
    Hou, Ming-Feng
    Chu, Pei-Yi
    CANCERS, 2021, 13 (12)
  • [42] The Potential of Hormonal Therapies for Treatment of Triple-Negative Breast Cancer
    Kirkby, Melanie
    Popatia, Alyanna M.
    Lavoie, Jessie R.
    Wang, Lisheng
    CANCERS, 2023, 15 (19)
  • [43] Triple-Negative Breast Cancer: Not Entirely Negative
    Leone, Jose Pablo
    Puhalla, Shannon
    ONCOLOGY-NEW YORK, 2013, 27 (09): : 856 - +
  • [44] Sesquiterpenoids from Inula britannica and Their Potential Effects against Triple-Negative Breast Cancer Cells
    Qi, Ruo-Yu
    Guo, Cong
    Peng, Xiao-Na
    Tang, Jiang-Jiang
    MOLECULES, 2022, 27 (16):
  • [45] Design, synthesis and biological evaluation of quinazoline derivatives as cytotoxic molecules of breast cancer triple-negative
    Matus-Meza, Audifas-Salvador
    Hernandez-Luis, Francisco
    Velasco-Velazquez, Marco
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [46] Theranostics for Triple-Negative Breast Cancer
    Choi, Hyeryeon
    Kim, Kwangsoon
    DIAGNOSTICS, 2023, 13 (02)
  • [47] Advanced Triple-Negative Breast Cancer
    Patel, Grisma
    Prince, Alison
    Harries, Mark
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [48] What is triple-negative breast cancer?
    Irvin, William J., Jr.
    Carey, Lisa A.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2799 - 2805
  • [49] Immunotherapy in Triple-Negative Breast Cancer
    Emens, Leisha A.
    CANCER JOURNAL, 2021, 27 (01): : 59 - 66
  • [50] Pembrolizumab in Triple-Negative Breast Cancer
    Altundag, Kadri
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (15): : 1435 - 1436